Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks

Jan‐Philipp Mallm(German Cancer Research Center), Murat Iskar(German Cancer Research Center), Naveed Ishaque(German Cancer Research Center), Lara C. Klett(German Cancer Research Center), Sabrina J. Kugler(German Cancer Research Center), José M. Muiño(Max Planck Institute for Molecular Genetics), Vladimir B. Teif(University of Essex), Alexandra M. Poos(German Cancer Research Center), Sebastian Großmann(German Cancer Research Center), Fabian Erdel(Centre National de la Recherche Scientifique), Daniele Tavernari(German Cancer Research Center), Sandra D. Koser(German Cancer Research Center), Sabrina Schumacher(German Cancer Research Center), Benedikt Brors(German Cancer Research Center), Rainer König(Jena University Hospital), Daniel Remondini, Martin Vingron(Max Planck Institute for Molecular Genetics), Stephan Stilgenbauer(University Hospital Ulm), Peter Lichter(German Cancer Research Center), Marc Zapatka(German Cancer Research Center), Daniel Mertens(German Cancer Research Center), Karsten Rippe(German Cancer Research Center)
Molecular Systems Biology
May 1, 2019
Cited by 62Open Access
Full Text

Abstract

In chronic lymphocytic leukemia (CLL), a diverse set of genetic mutations is embedded in a deregulated epigenetic landscape that drives cancerogenesis. To elucidate the role of aberrant chromatin features, we mapped DNA methylation, seven histone modifications, nucleosome positions, chromatin accessibility, binding of EBF1 and CTCF, as well as the transcriptome of B cells from CLL patients and healthy donors. A globally increased histone deacetylase activity was detected and half of the genome comprised transcriptionally downregulated partially DNA methylated domains demarcated by CTCF CLL samples displayed a H3K4me3 redistribution and nucleosome gain at promoters as well as changes of enhancer activity and enhancer linkage to target genes. A DNA binding motif analysis identified transcription factors that gained or lost binding in CLL at sites with aberrant chromatin features. These findings were integrated into a gene regulatory enhancer containing network enriched for B-cell receptor signaling pathway components. Our study predicts novel molecular links to targets of CLL therapies and provides a valuable resource for further studies on the epigenetic contribution to the disease.


Related Papers

No related papers found

Powered by citation graph analysis